Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Dose Escalation and Expansion Study Of PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors

NCT07300150 is registered in ClinicalTrials.gov with PAQ Therapeutics, Inc. as lead sponsor.

NCT NCT07300150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07300150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Dose Escalation and Expansion Study Of PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors
Lead sponsor
PAQ Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2025
Completion date
October 18, 2028
Enrollment
210 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non-small cell lung cancer, pancreatic cancer, solid tumor